SCA
EPZM

Secor Capital Advisors’s Epizyme, Inc EPZM Stock Holding History

Secor Capital Advisors’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-20,871
Closed -$259K – 318
2019
Q1 		$259K Sell
20,871
-146,164
-88% -$1.63M 0.05% 345
2018
Q4 		$1.03M Buy
+167,035
New +$1.28M 0.13% 221
2018
Q1 		– Sell
-73,854
Closed -$927K – 676
2017
Q4 		$927K Buy
73,854
+3,978
+6% +$57.8K 0.04% 292
2017
Q3 		$1.33M Buy
69,876
+30,470
+77% +$465K 0.13% 234
2017
Q2 		$595K Buy
+39,406
New +$596K 0.05% 329
2017
Q1 		– Sell
-27,195
Closed -$329K – 628
2016
Q4 		$329K Sell
27,195
-159,753
-85% -$1.67M 0.04% 395
2016
Q3 		$1.84M Buy
186,948
+126,392
+209% +$1.15M 0.2% 158
2016
Q2 		$620K Buy
+60,556
New +$675K 0.08% 336

Other funds holding EPZM

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Secor Capital Advisors's EPZM Position: Q2 2019 in Review

Secor Capital Advisors sold out of Epizyme, Inc (EPZM) in Q2 2019, closing a stake of 20,871 shares — an estimated $259K sold.

Secor Capital Advisors first reported a position in EPZM in Q2 2016 and held it in 8 quarters. The position peaked at $1.84M in Q3 2016. 134 funds tracked by Wall St. Rank hold EPZM as of Q2 2019.

  • Secor Capital Advisors reported no remaining Epizyme, Inc position as of Q2 2019 after selling out during the quarter.
  • Secor Capital Advisors sold 20,871 Epizyme, Inc shares in Q2 2019, an estimated $259K.
  • Secor Capital Advisors first reported a position in Epizyme, Inc in Q2 2016 and held it in 8 quarters.
  • Secor Capital Advisors's Epizyme, Inc position peaked at $1.84M in Q3 2016.
  • 134 funds tracked by Wall St. Rank held Epizyme, Inc as of Q2 2019.

Based on Secor Capital Advisors's 13F filing for Q2 2019.